Isolated pulmonary hypertension in scleroderma

Internal Medicine Journal

Volumn 35, Issue 1, 2005, Pages 28-33

  Cox, S R ^a   Walker, J G ^a   Coleman, M ^a   Rischmueller, M ^b   Proudman, S ^c   Smith, M D ^a   Ahern, M J ^a   Roberts Thomson, P J ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cumulative survival; Endothelin 1 receptor antagonists; Isolated pulmonary hypertension; Scleroderma; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE; CENTROMERE ANTIBODY; ENDOTHELIN RECEPTOR ANTAGONIST; LA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY;

ADULT; AGED; AUSTRALIA; CAPILLARY DENSITY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ECHOCARDIOGRAPHY; FEMALE; FINGER; FORCED EXPIRATORY VOLUME; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REGISTER; REVIEW; SCLERODERMA; SURVIVAL TIME; TELANGIECTASIA; ULCER;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SCLERODERMA, LIMITED; SOUTH AUSTRALIA; SURVIVAL ANALYSIS;

EID: 13844278187     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00646.x     Document Type: Review

References (14)

1. Roberts-Thomson PJ, Jones M, Hakendorf P, Kencana Dharmapatni AASS, Walker JG, MacFarlane JG et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J 2001; 31: 220-9.
2. Bond C, Pile KD, McNeil JD, Ahern MJ, Smith MD, Cleland LG et al. South Australian Scleroderma Rigister: analysis of deceased patients. Pathology 1998; 30: 386-90.
3. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
4. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97-9.
5. Budev MM, Arroliga AC, Jennings CA. Diagnosis and evaluation of pulmonary hypertension. Cleve Clin J Med 2003; 70: S9-17.
6. Silver RM. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 1996; 22: 825-40.
7. Al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD et al. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 1989; 16: 1038-42.
8. Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther 2002; 7: 9-19.
9. Masi AT, Rodnan GP, Medsger TA, Altman RD, D'Angelo WA, Fries JF et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1983; 23: 581-90.
10. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-81.
12. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001; 40: 453-9.
13. Roberts-Thomson PJ, Mould TL, Walker JG, Smith MD, Ahern MJ. Clinical utility of telangiectasia of hands in scleroderma and other rheumatic disorders. Asian Pac J Allergy Immunol 2002; 20: 7-12.
14. Ong YY, Nikoloutsopoulos T, Bond CP, Smith MD, Ahern MJ, Roberts-Thomson PJ. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998; 16: 81-6.